TYPE2 DIABETES
Clinical trials for TYPE2 DIABETES explained in plain language.
Never miss a new study
Get alerted when new TYPE2 DIABETES trials appear
Sign up with your email to follow new studies for TYPE2 DIABETES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Intensive diet and exercise may help control type 2 diabetes
Disease control OngoingThis study tests whether a 12-week program of either a very low-calorie diet or high-intensity exercise can improve blood sugar control in adults aged 40-70 who are newly diagnosed with type 2 diabetes and overweight. Participants are randomly assigned to one of these intensive l…
Matched conditions: TYPE2 DIABETES
Phase: NA • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Can a diabetes pill smooth out blood sugar after bariatric surgery?
Disease control ENROLLING_BY_INVITATIONThis study tests whether the drug dapagliflozin can help control blood sugar highs and lows in people who have had bariatric surgery, both with and without type 2 diabetes. About 30 participants will wear a continuous glucose monitor to track their sugar levels while taking the d…
Matched conditions: TYPE2 DIABETES
Phase: PHASE2 • Sponsor: Dasman Diabetes Institute • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
Gene test: does sitagliptin work better for some?
Knowledge-focused OngoingThis study looks at how the diabetes drug sitagliptin affects people who have a natural genetic change that lowers their DPP4 levels. Researchers will compare 20 adults with and without this gene change to see if the drug lowers blood sugar more effectively. The goal is to unders…
Matched conditions: TYPE2 DIABETES
Phase: PHASE4 • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated May 15, 2026 11:54 UTC
-
Massive diabetes drug showdown: 780,000 patients reveal which pill protects heart and kidneys
Knowledge-focused OngoingThis study looks at real-world data from over 780,000 people with type 2 diabetes to compare four common second-line medications: SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas. The goal is to see which ones are safest and most effective at prevent…
Matched conditions: TYPE2 DIABETES
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated May 13, 2026 16:03 UTC